While GLP-1s had mostly been prescribed for patients with type 2 diabetes as recently as two years ago (as of May 2024), the number of patients without a diabetes diagnosis using GLP-1s for weight loss has risen exponentially for example, they grew from 21K in 2019 to 174K in 2023, an increase of more than 700%
Every batch of Acetyl GLP-1+GIP is produced in facilities that adhere strictly to GMP, HACCP, and ISO 13485 standards
In the age of individualized medicine, the time has come to treat PD according to each patients specific needs, disease subtype, and likelihood of progression
Intake of nutrient and non-nutrient dietary antioxidants: Contribution of macromolecular antioxidant polyphenols in an elderly Mediterranean population
Consider adding lime juice to improve palatability
employers are planning to stop covering GLP-1 drugs for weight loss next year